Marché mondial de la biopsie liquide des cellules tumorales circulantes (CTC) – Tendances et prévisions de l'industrie jusqu'en 2030

Analyse et taille du marché de la biopsie liquide des cellules tumorales circulantes (CTC)

Les facteurs essentiels contribuant à la croissance du marché de la biopsie liquide des cellules tumorales circulantes (CTC) au cours de la période de prévision 2023-2030 comprennent la demande croissante de biopsie liquide des cellules tumorales circulantes (CTC) en raison de leur efficacité, la prévalence croissante du cancer due à divers troubles génétiques, l'augmentation de la consommation d'alcool et les changements de mode de vie. Parallèlement à cela, l'utilisation croissante des CTC pour le dépistage des métastases chez les patients et les études précliniques des nouveaux médicaments contre le cancer contribuent à la croissance du marché. En outre, l'introduction de la nanotechnologie pour améliorer la sensibilité et l'efficacité de l'isolement et de la détection des CTC, l'adoption généralisée de la biopsie liquide à base de CTC pour une récupération rapide et la demande croissante de procédures de diagnostic mini-invasives (MI) stimulent considérablement la croissance du marché.

Français Data Bridge Market Research analyse que le marché de la biopsie liquide des cellules tumorales circulantes (CTC), qui était de 1 173,84 millions USD en 2022, devrait atteindre 4 170,06 millions USD d’ici 2030, avec un TCAC de 17,17 % au cours de la période de prévision de 2023 à 2030. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l’épidémiologie des patients, l’analyse du pipeline, l’analyse des prix et le cadre réglementaire.

Portée et segmentation du marché de la biopsie liquide des cellules tumorales circulantes (CTC)

Market Definition

The liquid biopsy is a type of non-invasive blood test which identifies circulating tumor cells and tumor DNA fragments which are released in the blood by primary tumors and metastatic sites. It is an alternative to surgical biopsy procedure, and it allows surgeon to detect cancer at a very early stage. The circulating tumor cells function as a seed of metastases. The patients who have developed solid tumors it is found in them. The detection and quantification of tumor cells in the blood of cancer patients is allowed by the testing of circulating tumor cells. There are various types of biological phenotypes of circulating tumor cells (CTCs) such as stem cell-like or mixed, mesenchymal or epithelial. These phenotypes are present in blood in a very small quantity and due to which, a phase of isolation-enrichment is required in their detection. 

Global Circulating Tumor Cells (CTC) Liquid Biopsy Dynamics

Drivers

• Rising prevalence of cancer

The rising prevalence of different types of cancer is boosting the market’s growth. The increasing number of cancer cases across the world is fuelling the demand of liquid biopsy. Breast cancer was the most common cancer 2020 with 2.26 million cases and further lung cancer with 2.21 million cases. The rising prevalence of cancer can be reduced through early detection of cancer and appropriate treatment. Circulating cancer cells are suitable for developing preclinical models, particularly 3D organoid cultures, for use in drug screening, disease modelling, genome editing, and organoid biobanks, thus significantly driving the market’s growth.

• Awareness initiatives by global health organizations and government

The governments in various countries and global health organizations are spreading awareness about cancer and other growing diseases. National Cancer Control program of WHO, is a public health program aiming to reduce the growing number of cancer deaths and improve the life of cancer patients. Furthermore, the National Breast and Cervical Cancer Early Detection Program (NBCCEDP), initiated by the US Centers for Diseases and Prevention (CDC) in 1991, provides breast cancer screening and diagnosis for uninsured and low-income patients in the US every year. The rising awareness in people about the effects and necessity to cure the diseases is increasing the liquid biopsy tests and treatments further driving the market’s growth.

Opportunities

• Growth opportunities in emerging countries

The developing countries such as India, Brazil, Turkey, Russia, South Africa, China, South Korea are offering major growth opportunities for liquid biopsy market. The major factors owing to the growth of liquid biopsy market in developing economies include improving healthcare infrastructure, higher cancer prevalence, large patient population, increasing disposable income, and growing medical tourism. Thus, there are number of opportunities for the market’s growth.

• Increasing R&D associated with liquid biopsy

The new research and development in liquid biopsies have revolutionized several related technologies, clinical oncology, devising personalized therapeutic regimens, offering easy tumor sampling, continuous monitoring by repeated sampling, and screening for therapeutic resistance. The increasing research and development is further increasing the demand of liquid biopsy which further increases the market’s growth.

Restraints/Challenges

• The lower sensitivity of certain liquid biopsies

In liquid biopsies certain procedures are technically challenging such as Detecting ctDNA because the levels of ctDNA of any given cancer mutation can be very low in the plasma of a cancer patient, after treatment or surgery. ctDNA is not applicable to all cancers, some tumor types are bad ctDNA shedders such as gliomas and sarcomas, and acts as an hurdle for ctDNA profiling. The reason for low ctDNA levels is not clear but is considered to be associated with tumor vascularity, location or the blood-brain barrier. Thus, the lower sensitivity of certain liquid biopsies is a major challenge for the market’s growth.

•  Unclear reimbursement scenario

Limited reimbursement (non-coverage for panel-based tests) restricts the growth of liquid biopsy testing. The guidelines of NCD proved favorable for approval of Foundation One’s genomic profiling assay, but there are possibilities that it can work against other companies developing NGS-panel tests under LDT scenario. Multigene NGS tests have not secured FDA approval or reimbursement coverage, it is up to Medicare Administrative Contractors (MACs) to approve coverage when a company seeks a local coverage determination (LCD) if multigene NGS tests have not secured FDA approval or reimbursement coverage. These unclear reimbursement scenarios will be creating an unfavorable situation for liquid biopsy market’s growth.

This circulating tumor cells (CTC) liquid biopsy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the circulating tumor cells (CTC) liquid biopsy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In November 2021, Myriad Genetics, Inc. announced that it has presented the data at San Antonio Breast Cancer Symposium and highlighted the value of genetic testing in breast cancer treatment. This will help Myriad Genetics, Inc. to advance the launch of novel product in the market. This advancement will further fuel the growth of liquid biopsy market’s growth.
• In February 2021, Menarini Silicon Biosystems announced the launch of CellMag product line for manual enrichment and staining of circulating tumor cells. This has helped Menarini Silicon Biosystems to increase its product line and will significantly boosts the market’s growth.

Global Circulating Tumor Cells (CTC) Liquid Biopsy Market Scope

The circulating tumor cells (CTC) liquid biopsy market is segmented on the basis of technology, application, clinical application, sample type, product, specimen and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Technology

• CTC Detection Methods
• CTC Enrichment Methods
• Ex Vivo Positive Selection
• Molecular (RNA)-Based Technologies
• Functional In Vitro Cell Invasion Assay
• Xenotransplantation Models
• Microchips
• Single Spiral Microchannel
• Negative Selection & Immunocytochemical Technologies

 Application

• Cancer Application
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Melanoma
• Other Cancers
• Non-Cancer Applications
• Non-Invasive Prenatal Testing (NIPT)
• Organ Transplantation
• Infectious Disease Testing

Clinical Application

• Early Cancer Screening
• Diagnosis
• Therapy Selection
• Treatment Monitoring
• Prognosis and Recurrence Monitoring

Sample Type

• Blood
• Urine
• Saliva
• Cerebrospinal Fluid
• Others

Product

• Kits & Reagents
• Blood Collection Tubes
• Devices or System

Specimen

• Blood
• Bone Marrow
• Other Body Fluids

End User

• Research & Academic Institutes
• Reference Laboratories
• Hospitals
• Physician Laboratories

Global Circulating Tumor Cells (CTC) Liquid Biopsy Market Regional Analysis/Insights

The circulating tumor cells (CTC) liquid biopsy market is analysed and market size insights and trends are provided, technology, application, clinical application, sample type, product, specimen and end user as referenced above.

The countries covered in the circulating tumor cells (CTC) liquid biopsy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates global circulating tumor cells (CTC) liquid biopsy market. This is majorly due to the growing adoption of the liquid biopsy in the North American region for diagnosis of cancer. There are rapidly growing cases of cancer in US which has contributed in the dominance of North America in the global liquid biopsy market.

L'Asie-Pacifique devrait connaître une croissance au cours de la période de prévision de 2023 à 2030. Les principaux facteurs contribuant à la croissance du marché en Asie-Pacifique comprennent l'augmentation du revenu disponible, la sensibilisation croissante aux techniques de biopsie liquide et l'adoption croissante de techniques avancées dans les hôpitaux, les cliniques, les laboratoires de diagnostic pour le diagnostic et l'augmentation des dépenses de santé. En outre, la pénétration croissante des hôpitaux et des centres de diagnostic stimule encore davantage la croissance du marché dans la région Asie-Pacifique.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces de Porter, les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.   

Analyse du paysage concurrentiel et des parts de marché mondiales de la biopsie liquide des cellules tumorales circulantes (CTC)

Le paysage concurrentiel du marché de la biopsie liquide des cellules tumorales circulantes (CTC) fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination de l'application. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché de la biopsie liquide des cellules tumorales circulantes (CTC).

Certains des principaux acteurs opérant sur le marché de la biopsie liquide des cellules tumorales circulantes (CTC) sont :

• QIAGEN (Allemagne)
• Bio-Techne (États-Unis)
• Precision Medical Group, LLC. (États-Unis)
• Aviva Systems Biological Corporation (États-Unis)
• Biocept, Inc. (États-Unis)
• Fluxion Biosciences, Inc. (États-Unis)
• Greiner Bio-One International GmbH (Autriche)
• Ikonisys (États-Unis)
• Miltenyi Biotec (Allemagne)
• IVDiagnostics (États-Unis)
• BioFluidica (États-Unis)
• Canopus Medical (Suède)
• Biolidics Limited (Singapour)
• Creativ MicroTech, Inc. (États-Unis)
• LungLife AI, Inc. (États-Unis)
• Epic Sciences (États-Unis)
• Rarecells Diagnostics (France)
• ScreenCell (France)
• Menarini Silicon Biosystems (États-Unis)

SKU-56369